Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Mirum Pharmaceuticals, Inc. (MIRM)
|
|
| Income Statement |
|
|
|
| Standardized | As Reported |
Annual | Quarterly | TTM |
|
| In millions, except per share items | Jun-30-23 | Mar-31-23 | Dec-31-22 | Sep-30-22 | Jun-30-22 | Mar-31-22 | Dec-31-21 | Sep-30-21 |
| | 10-Q | 10-Q | 8-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q |
| Revenues: |
| Research and development | | | 31.1 | | | | | |
| Product sales, net | | | 27.9 | | | | | |
| Total revenues [+] | 37.5 | 31.6 | 27.9 | 18.8 | 17.5 | 12.9 | 3.1 | 5.0 |
| Royalties | | | 31.1 | | | | | |
| Products | | | 27.9 | | | | | |
| Revenue growth | 114.5% | 145.1% | 789.3% | 275.6% | 58.9% | | | |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 37.5 | 31.6 | 27.9 | 18.8 | 17.5 | 12.9 | 3.1 | 5.0 |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Selling, general and administrative [+] | 61.8 | 58.7 | 26.5 | 51.7 | 48.9 | 45.6 | 48.7 | 47.8 |
| General and administrative | | | | | | | 48.7 | |
| Research and development | 22.0 | 23.5 | | 26.2 | 25.4 | 24.1 | 27.8 | 30.5 |
| Other operating expenses | -22.0 | -23.5 | 35.6 | -26.2 | -25.4 | -24.1 | -27.8 | -30.5 |
| EBITDA [+] | -22.9 | -25.8 | | -31.8 | -30.8 | -32.4 | -45.2 | -42.7 |
| EBITDA growth | -25.6% | -20.3% | -24.5% | -25.6% | -17.4% | -31.8% | 22.7% | 97.5% |
| EBITDA margin | -61.2% | -81.7% | -122.4% | -169.3% | -176.4% | -251.3% | -1441.5% | -854.8% |
| Depreciation | 0.1 | 0.0 | | 0.1 | 0.1 | 0.0 | 0.3 | 0.1 |
| EBITA | -23.1 | -25.8 | -34.2 | -31.9 | -30.9 | -32.4 | -45.6 | -42.8 |
| EBITA margin | -61.5% | -81.8% | -122.4% | -169.8% | -177.0% | -251.6% | -1452.4% | -856.5% |
| Amortization of intangibles | 1.2 | 1.3 | | 1.0 | 0.5 | 0.3 | | |
| EBIT [+] | -24.3 | -27.1 | -34.2 | -32.9 | -31.4 | -32.7 | -45.6 | -42.8 |
| EBIT growth | -22.8% | -17.1% | -25.0% | -23.2% | -15.9% | -31.2% | 23.3% | 97.2% |
| EBIT margin | -64.7% | -85.9% | -122.4% | -175.1% | -179.8% | -253.9% | -1452.4% | -856.5% |
| Interest income, net [+] | 3.6 | 2.3 | -4.4 | 1.4 | 0.3 | 0.1 | 0.1 | 0.1 |
| Interest expense | | | 4.4 | | | | | |
| Interest income | 3.6 | 2.3 | | 1.4 | 0.3 | 0.1 | 0.1 | 0.1 |
| Other income (expense), net [+] | -53.1 | -5.1 | 2.2 | -4.2 | -2.3 | -3.9 | 103.1 | -4.3 |
| Unrealized gain/loss on derivatives | | | 0.7 | | | | | |
| Pre-tax income | -73.7 | -29.9 | -36.3 | -35.7 | -33.5 | -36.6 | 57.6 | -47.1 |
| Income taxes | 0.3 | 0.2 | 0.1 | 0.0 | -6.6 | 0.0 | 0.0 | 0.0 |
| Tax rate | | | | | 19.6% | | 0.0% | |
| Net income | -74.0 | -30.1 | -36.4 | -35.7 | -26.9 | -36.6 | 57.5 | -47.1 |
| Net margin | -197.5% | -95.4% | -130.5% | -190.1% | -154.0% | -283.9% | 1833.8% | -942.2% |
| |
| Basic EPS [+] | ($1.94) | ($0.80) | | ($1.02) | ($0.84) | ($1.17) | $1.90 | ($1.55) |
| Growth | 132.1% | -31.6% | | -34.1% | -42.3% | -30.3% | -228.8% | 81.3% |
| Diluted EPS [+] | ($1.94) | ($0.80) | | ($1.02) | ($0.84) | ($1.17) | $1.90 | ($1.55) |
| Growth | 132.2% | -31.6% | | -34.1% | -42.3% | -30.3% | -228.8% | 81.3% |
| |
| Shares outstanding (basic) [+] | 38.1 | 37.7 | | 34.9 | 32.2 | 31.3 | 30.3 | 30.4 |
| Growth | 18.5% | 20.4% | | 15.0% | 6.2% | 4.0% | 20.1% | 20.8% |
| Shares outstanding (diluted) [+] | 38.1 | 37.7 | | 34.9 | 32.2 | 31.3 | 30.3 | 30.4 |
| Growth | 18.4% | 20.4% | | 15.0% | 6.3% | 4.0% | 20.1% | 20.8% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|